New chief medical officer at food allergy company Aimmune

23 June 2016

Aimmune Therapeutics (Nasdaq: AIMT), a USA-based biopharma company developing treatments for life-threatening food allergies, has appointed Daniel Adelman its chief medical officer.

Dr Adelman is a renowned allergist and immunologist who spent seven years as chief medical officer at Alvine Pharmaceuticals, a privately-held US biotech focused on autoimmune and inflammatory diseases, particularly celiac disease.

He held the same role during five years at US pharma Sunesis Pharmaceuticals (Nasdaq: SNSS) and previously worked in various positions at Pharmacyclics and Genentech.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK